Additional Relevant Details
Emicizumab treatment continued to demonstrate a reduction in median ABR, resulting in patients with severe haemophilia A achieving an ABR of 1.4, 0.2 and 0 for the emicizumab 0.3, 1 and 3 mg/kg/week treatment groups respectively. This equated to a reduction in ABR of greater than 95% in each group. The safety profile of emicizumab was consistent with that previously observed in the Phase I study. The results of this longer follow-up confirm data previously presented at the International Society on Thrombosis and Haemostasis Congress in June 2015. Data from the first 12 week period of treatment, originally presented during the annual meeting of the American Society of Hematology in 2014, were recently published in the New England Journal of Medicine1.